181 related articles for article (PubMed ID: 33165845)
1. Next-Generation Sequencing Technology to Identify Minimal Residual Disease in Lymphoid Malignancies.
Kotrova M; Darzentas N; Pott C; Brüggemann M;
Methods Mol Biol; 2021; 2185():95-111. PubMed ID: 33165845
[TBL] [Abstract][Full Text] [Related]
2. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.
Brüggemann M; Kotrová M; Knecht H; Bartram J; Boudjogrha M; Bystry V; Fazio G; Froňková E; Giraud M; Grioni A; Hancock J; Herrmann D; Jiménez C; Krejci A; Moppett J; Reigl T; Salson M; Scheijen B; Schwarz M; Songia S; Svaton M; van Dongen JJM; Villarese P; Wakeman S; Wright G; Cazzaniga G; Davi F; García-Sanz R; Gonzalez D; Groenen PJTA; Hummel M; Macintyre EA; Stamatopoulos K; Pott C; Trka J; Darzentas N; Langerak AW;
Leukemia; 2019 Sep; 33(9):2241-2253. PubMed ID: 31243313
[TBL] [Abstract][Full Text] [Related]
3. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS.
Knecht H; Reigl T; Kotrová M; Appelt F; Stewart P; Bystry V; Krejci A; Grioni A; Pal K; Stranska K; Plevova K; Rijntjes J; Songia S; Svatoň M; Froňková E; Bartram J; Scheijen B; Herrmann D; García-Sanz R; Hancock J; Moppett J; van Dongen JJM; Cazzaniga G; Davi F; Groenen PJTA; Hummel M; Macintyre EA; Stamatopoulos K; Trka J; Langerak AW; Gonzalez D; Pott C; Brüggemann M; Darzentas N;
Leukemia; 2019 Sep; 33(9):2254-2265. PubMed ID: 31227779
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS.
Scheijen B; Meijers RWJ; Rijntjes J; van der Klift MY; Möbs M; Steinhilber J; Reigl T; van den Brand M; Kotrová M; Ritter JM; Catherwood MA; Stamatopoulos K; Brüggemann M; Davi F; Darzentas N; Pott C; Fend F; Hummel M; Langerak AW; Groenen PJTA;
Leukemia; 2019 Sep; 33(9):2227-2240. PubMed ID: 31197258
[TBL] [Abstract][Full Text] [Related]
5. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
Kotrova M; Trka J; Kneba M; Brüggemann M
Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
[TBL] [Abstract][Full Text] [Related]
6. Detection of clonal immunoglobulin and T-cell receptor gene recombination in hematological malignancies: monitoring minimal residual disease.
García-Castillo H; Barros-Núñez P
Cardiovasc Hematol Disord Drug Targets; 2009 Jun; 9(2):124-35. PubMed ID: 19519371
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies.
Hussaini MO; Srivastava J; Lee LW; Nishihori T; Shah BD; Alsina M; Pinilla-Ibarz J; Shain KH
Arch Pathol Lab Med; 2022 Apr; 146(4):485-493. PubMed ID: 34343238
[TBL] [Abstract][Full Text] [Related]
8. Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.
Shin S; Hwang IS; Kim J; Lee KA; Lee ST; Choi JR
Ann Lab Med; 2017 Jul; 37(4):331-335. PubMed ID: 28445014
[TBL] [Abstract][Full Text] [Related]
9. High-throughput sequencing of T-cell receptor alpha chain clonal rearrangements at the DNA level in lymphoid malignancies.
Komkov A; Miroshnichenkova A; Nugmanov G; Popov A; Pogorelyy M; Zapletalova E; Jelinkova H; Pospisilova S; Lebedev Y; Chudakov D; Olshanskaya Y; Plevova K; Maschan M; Mamedov I
Br J Haematol; 2020 Mar; 188(5):723-731. PubMed ID: 31587259
[TBL] [Abstract][Full Text] [Related]
10. PCR Technology to Identify Minimal Residual Disease.
Cazzaniga G; Songia S; Biondi A;
Methods Mol Biol; 2021; 2185():77-94. PubMed ID: 33165844
[TBL] [Abstract][Full Text] [Related]
11. Perspective: sensitive detection of residual lymphoproliferative disease by NGS and clonal rearrangements-how low can you go?
Hansen MH; Cédile O; Larsen TS; Abildgaard N; Nyvold CG
Exp Hematol; 2021 Jun; 98():14-24. PubMed ID: 33823225
[TBL] [Abstract][Full Text] [Related]
12. Next-Generation Sequencing-Based Clonality Detection of Immunoglobulin Gene Rearrangements in B-Cell Lymphoma.
van Bladel DAG; van der Last-Kempkes JLM; Scheijen B; Groenen PJTA;
Methods Mol Biol; 2022; 2453():7-42. PubMed ID: 35622318
[TBL] [Abstract][Full Text] [Related]
13. High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges.
Langerak AW; Brüggemann M; Davi F; Darzentas N; van Dongen JJM; Gonzalez D; Cazzaniga G; Giudicelli V; Lefranc MP; Giraud M; Macintyre EA; Hummel M; Pott C; Groenen PJTA; Stamatopoulos K;
J Immunol; 2017 May; 198(10):3765-3774. PubMed ID: 28416603
[TBL] [Abstract][Full Text] [Related]
14. ClonoSEQ assay for the detection of lymphoid malignancies.
Monter A; Nomdedéu JF
Expert Rev Mol Diagn; 2019 Jul; 19(7):571-578. PubMed ID: 31179776
[No Abstract] [Full Text] [Related]
15. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
van der Velden VH; Cazzaniga G; Schrauder A; Hancock J; Bader P; Panzer-Grumayer ER; Flohr T; Sutton R; Cave H; Madsen HO; Cayuela JM; Trka J; Eckert C; Foroni L; Zur Stadt U; Beldjord K; Raff T; van der Schoot CE; van Dongen JJ;
Leukemia; 2007 Apr; 21(4):604-11. PubMed ID: 17287850
[TBL] [Abstract][Full Text] [Related]
16. Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial.
Genuardi E; Romano G; Beccuti M; Alessandria B; Mannina D; Califano C; Rota Scalabrini D; Cortelazzo S; Ladetto M; Ferrero S; Calogero RA; Cordero F
Br J Haematol; 2021 Jul; 194(2):378-381. PubMed ID: 34002365
[TBL] [Abstract][Full Text] [Related]
17. [Molecular biology in malignant blood diseases. Clinical applications. Study of immunoglobulin and T-cell receptor genes and molecular analysis of the translocations].
González M; García-Sanz R; Vargas M; Balanzategui A; Chillón MC; Mateos MV; San Miguel JF
Sangre (Barc); 1996 Aug; 41(4):321-34. PubMed ID: 8984674
[No Abstract] [Full Text] [Related]
18. Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies.
Sánchez R; Ayala R; Martínez-López J
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185671
[TBL] [Abstract][Full Text] [Related]
19. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders.
Stewart JP; Gazdova J; Darzentas N; Wren D; Proszek P; Fazio G; Songia S; Alcoceba M; Sarasquete ME; Villarese P; van der Klift MY; Heezen KC; McCafferty N; Pal K; Catherwood M; Kim CS; Srivastava S; Kroeze LI; Hodges E; Stamatopoulos K; Klapper W; Genuardi E; Ferrero S; van den Brand M; Cazzaniga G; Davi F; Sutton LA; Garcia-Sanz R; Groenen PJTA; Macintyre EA; Brüggemann M; Pott C; Langerak AW; Gonzalez D;
Blood Adv; 2021 Aug; 5(16):3188-3198. PubMed ID: 34424321
[TBL] [Abstract][Full Text] [Related]
20. Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection.
Theunissen PMJ; de Bie M; van Zessen D; de Haas V; Stubbs AP; van der Velden VHJ
Leuk Res; 2019 Jan; 76():98-104. PubMed ID: 30389174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
